Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J, Garaigorta U, Pérez P, Lázaro-Frías A, Zamora C, Gastaminza P, Del Fresno C, Casasnovas JM, Sorzano CÓS, Sancho D, Esteban M. García-Arriaza J, et al. Among authors: zamora c. J Virol. 2021 Mar 10;95(7):e02260-20. doi: 10.1128/JVI.02260-20. Epub 2021 Jan 7. J Virol. 2021. PMID: 33414159 Free PMC article.
A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P, Lázaro-Frías A, Zamora C, Sánchez-Cordón PJ, Astorgano D, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. Pérez P, et al. Among authors: zamora c. Front Immunol. 2022 Jan 27;12:824728. doi: 10.3389/fimmu.2021.824728. eCollection 2021. Front Immunol. 2022. PMID: 35154086 Free PMC article.
Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate.
Villadiego J, García-Arriaza J, Ramírez-Lorca R, García-Swinburn R, Cabello-Rivera D, Rosales-Nieves AE, Álvarez-Vergara MI, Cala-Fernández F, García-Roldán E, López-Ogáyar JL, Zamora C, Astorgano D, Albericio G, Pérez P, Muñoz-Cabello AM, Pascual A, Esteban M, López-Barneo J, Toledo-Aral JJ. Villadiego J, et al. Among authors: zamora c. Nat Neurosci. 2023 Feb;26(2):226-238. doi: 10.1038/s41593-022-01242-y. Epub 2023 Jan 9. Nat Neurosci. 2023. PMID: 36624276
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
Perdiguero B, Marcos-Villar L, López-Bravo M, Sánchez-Cordón PJ, Zamora C, Valverde JR, Sorzano CÓS, Sin L, Álvarez E, Ramos M, Del Val M, Esteban M, Gómez CE. Perdiguero B, et al. Among authors: zamora c. Front Immunol. 2023 Jun 19;14:1160065. doi: 10.3389/fimmu.2023.1160065. eCollection 2023. Front Immunol. 2023. PMID: 37404819 Free PMC article.
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.
Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo ML, Lou G, Franceschini L, Esteban I, Sánchez-Cordón PJ, Zamora C, Sorzano CÓS, Jordá L, Codó L, Gelpí JL, Sisteré-Oró M, Meyerhans A, Thielemans K, Martínez-Jiménez F, López-Vigas N, García F, Alonso MJ, Plana M, Esteban M, Gómez CE. Marcos-Villar L, et al. Among authors: zamora c. NPJ Vaccines. 2024 Mar 6;9(1):53. doi: 10.1038/s41541-024-00838-8. NPJ Vaccines. 2024. PMID: 38448450 Free PMC article.
293 results